

CLINICAL SCIENCE

Guidance for Authors

CONTENTS

	<i>page</i>
1. Policy of the Journal	
1.1. Scope	i
1.2. The Editorial Board	i
1.3. The editorial process	i
1.4. Ethics of investigations on human subjects	ii
1.5. Originality of papers	ii
2. Submission of Manuscripts: General Information and Format	
2.1. General	ii
2.2. Full papers	ii
2.3. Short Communications	iii
2.4. Correspondence	iii
2.5. Arrangements for large amounts of information	iii
2.6. Proof corrections	iii
2.7. Offprints.	iii
2.8. Availability on MEDLINE	iii
3. Miscellaneous Notes	
3.1. Abbreviations	iv
3.2. Anatomical nomenclature	iv
3.3. Animals, plants and micro-organisms	iv
3.4. Buffers and salts	iv
3.5. Doses	iv
3.6. Enzymes	iv
3.7. Evaluation of measurement procedures	iv
3.8. Figures and Tables	iv
3.9. Footnotes	v
3.10. Isotope measurements	v
3.11. Radionuclide applications in man	v
3.12. Methods	v
3.13. Nomenclature of disease	v
3.14. Powers in Tables and Figures	v
3.15. References	v
3.16. Solutions	vi
3.17. Spectrophotometric data	vi
3.18. Spelling	vi
3.19. Statistics	vi
3.20. Trade names	vi
3.21. Computer modelling	vi
4. Units: The SI System	vii
5. Abbreviations, Conventions etc.	vii

1. POLICY OF THE JOURNAL

1.1. *Scope*

Clinical Science publishes papers in the field of clinical investigation, provided they are of a suitable standard and contribute to the advancement of knowledge in this field. The term 'clinical investigation' is used in its broad sense to include studies in animals and the whole range of biochemical, physiological, immunological and other approaches that may have relevance to disease in man. Studies which are confined to normal subjects, or animals, or are purely methodological in nature may be acceptable. The material presented should permit conclusions to be drawn and should not be only of a preliminary nature. The journal publishes four types of manuscript, namely invited Editorial Reviews, Full Papers, Short Communications and Correspondence. In addition, *Clinical Science* publishes abstracts of the proceedings of the Medical Research Society and also that Society's Annual Guest Lecture.

1.2. *The Editorial Board*

The Board comprises Editors for the Medical Research Society and the Biochemical Society and a Chairman and Deputy Chairman who are drawn alternately from the two Societies. Members of the Board retire after a maximum of 5 years; the Chairman serves in his capacity for 2 years. The membership of the Board is designed to cover as wide a range of interests as possible.

The main function of the Board is to decide on the acceptability of submitted papers, but it also deals with general matters of editorial policy. Financial policy is dealt with separately by the Committee of Management.

1.3. *The editorial process*

A submitted paper is first read by the Chairman of the Editorial Board who then sends it to an Editor. The latter considers the paper in detail and sends it to one or more referees (who remain anonymous) from outside the membership of the Board. The Editor returns it with his recommendation to the Chairman who then writes formally to

the authors. The ultimate responsibility of acceptance for publication lies with the Chairman. If the Chairman is for any reason unavailable, the Deputy Chairman assumes this function.

1.4. *Ethics of investigations on human subjects*

Authors must state in the text of their paper the manner in which they have complied, where necessary, with the recommendations on human investigations published in the Medical Research Council report of 1962/63 [*British Medical Journal* (1964) ii, 178–180]. Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used and the fact that such consent has been given should be recorded in the paper. Papers should also state that the Ethical Committee of the Institution in which the work was performed has given approval to the protocol. The Editorial Board will not accept papers the ethical aspects of which are, in the Board's opinion, open to doubt.

1.5. *Originality of papers*

Submission of a paper to the Editorial Board is taken to imply that it reports unpublished work, that it is not under consideration for publication elsewhere and that, if accepted for publication by *Clinical Science*, it will not be published elsewhere in the same form, either in English or in any other language, without the consent of the Editorial Board. This does not usually apply to previous publication of oral communications in brief abstract form. In such cases authors should enclose copies of the abstracts. When a paper has been accepted for publication the author, or in the case of multiple authorship the author with whom correspondence has taken place, will be asked to sign a statement vesting the copyright in the Editorial Board. Requests for consent for reproduction of material published in *Clinical Science* should be addressed to the Chairman of the Editorial Board.

2. SUBMISSION OF MANUSCRIPTS: GENERAL INFORMATION AND FORMAT

2.1. *General*

Papers submitted for publication should be sent to the Chairman of the Editorial Board (Dr D. J. Galton, Department of Medicine, St Bartholomew's Hospital, West Smithfield, London EC1M 6BQ).

The submission should contain three copies (of which two may be photocopies) of the typescript,

Tables, Figures etc. The authors should retain one copy of the paper. The Editorial Board does not accept responsibility for damage or loss of papers submitted, although great care is taken to ensure safety and confidentiality of the typescript during the editorial process. In the case of multiple authorship, the covering letter should indicate that the approval of all co-authors has been obtained.

Papers should be presented so that they are intelligible to the non-specialist reader of the journal. This is particularly important in highly specialized fields and a very brief résumé of the current state of knowledge is usually helpful. Certain types of material, e.g. mathematical formulations requiring more than trivial derivations, should be given in a separate Appendix.

Where the reader is referred to previous works by the same author(s) for important details relevant to the present work, it often speeds up assessment if reprints are enclosed with the typescript. This is of particular importance in relation to methodology.

The dates of receipt and acceptance of the paper will be published. If the paper has to be returned to the authors for revision and is not resubmitted within 1 month, the date of receipt will be revised accordingly. For Short Communications the published date will always be that of receipt of the final version. It is emphasized that badly presented or unduly long papers will be returned for revision and delays in publication will be inevitable. Similar delays will be incurred if the typescript is not prepared strictly in accordance with the instructions detailed below.

2.2. *Full papers*

The authors should refer to a current issue of *Clinical Science* to make themselves familiar with the general layout. Concise presentation is very important for rising costs are a severe constraint on space. **The length of manuscript and the number of Figures and Tables must be kept to a minimum.** Extensive Tables of data can be deposited with the Royal Society of Medicine (see 2.5). *Guidance for Authors* is usually published in the January issue of the journal, and revised periodically.

Typescripts should be, in general, arranged as follows:

(a) *Title page.* Title: this should be as informative as possible, since titles of papers are being increasingly used in indexing and coding for information storage and retrieval. The title should indicate the species in which the observations reported have been made. The numbering of parts in a series of papers is not permitted.

List of authors' names (degrees and appointments are not required).

Laboratory or Institute of origin.

Key words: for indexing the subject of the paper; they should, if possible, be selected from the current issues of 'Medical Subject Headings' (MeSH), produced by the *Index Medicus*.

Short title: for use as a running heading in the printed text; it should not exceed forty-five characters and spaces.

Author for correspondence: the name and address of the author to whom queries and requests for reprints should be sent.

(b) **Summary.** This should be a brief statement arranged in **numbered paragraphs** of what was done, what was found and what was concluded and should rarely exceed 250 words. Contributors from non-English speaking countries are invited to include a translation of the summary in their own language. Abbreviations should be avoided as far as possible and must be defined. Statistical and methodological details including exact doses should also be avoided unless they are essential to the understanding of the summary.

(c) **Introduction.** This should contain a clear statement of the reason for doing the work, but should not include either the findings or the conclusions.

(d) **Methods.** The aim should be to give sufficient information in the text or by reference to permit the work to be repeated without the need to communicate with the author.

(e) **Results.** This section should not include material appropriate to the Discussion section.

(f) **Discussion.** This should not contain results and should be pertinent to the data presented.

(g) **Acknowledgments.** These should be as brief as possible.

(h) **References.** See p. v for the correct format.

(i) **Figures and Tables.** See p. iv.

2.3. Short Communications

The Short Communication should describe completed work, and should not be merely a preliminary communication. The format of Short Communications should be similar to that of Full Papers, but should not exceed 1200 words of text. **One Figure or Table** is allowed, but if neither is included the text may be expanded to 1400 words. The passage of Short Communications through the editorial process can frequently be expedited and contributors are encouraged to take advantage of these facilities when rapid publication is of importance and the material can be presented concisely.

The paper should appear in print within 3 months of acceptance. When submitting Short Communications, authors should make it quite clear that the work is intended to be treated as a Short Communication.

2.4. Correspondence

Letters containing critical assessments of material published in *Clinical Science*, including Editorial Reviews, will be considered for the Correspondence section of the journal. Such letters should be sent to the Chairman of the Editorial Board within 6 months of the appearance of the article concerned. They will be sent to the authors for comment and both the letter and any reply by the author will be published together. Further correspondence arising therefrom will also be considered for publication. Consideration will also be given to publication of letters on ethical matters.

2.5. Arrangements for large amounts of information

It is impracticable to publish very large sets of individual values or very large numbers of diagrams, and under these circumstances a summary of the information only should be included in the paper. The information from which the summary was derived should be submitted with the typescript and, if the latter is accepted, the Editors may ask for a copy of the full information and diagrams to be deposited with the Librarian, the Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE, who will issue copies on request. Experience has shown that such requests are frequently received.

2.6. Proof corrections

These are expensive and corrections of other than printers' errors may have to be charged to the author.

2.7. Offprints

Fifty offprints are supplied free and additional copies may be obtained at terms, based upon the cost of production, that will be given with the proofs. All offprints should be ordered when the proofs are returned.

2.8. Availability on MEDLINE

Summaries of papers in *Clinical Science* are available on-line on teleprinters participating in the MEDLINE system run by the National Library of Medicine, National Institutes of Health, Bethesda, Maryland, U.S.A.

3. MISCELLANEOUS NOTES

3.1. Abbreviations

Abbreviations should be avoided; if used they must be defined at the first mention; new abbreviations should be coined only for unwieldy names which occur frequently. Abbreviations should not appear in the title nor, if possible, in the Summary. A list of accepted abbreviations is on p. vi. Numbers, not initials, should be used for patients and subjects.

3.2. Anatomical nomenclature

This should follow the recommendations of the International Anatomical Nomenclature Committee (1966) *Nomina Anatomica*, 3rd edn, Excerpta Medica Foundation, Amsterdam.

3.3. Animals, plants and micro-organisms

The full binomial specific names should be given at first mention for all experimental animals other than common laboratory animals. The strain and, if possible, the source of laboratory animals should be stated. Thereafter in the text, single letter abbreviations may be given for the genus; if two genera with the same initial letter are studied, abbreviations such as *Staph.* and *Strep.* should be used.

3.4. Buffers and salts

The acidic and basic components should be given, together with the pH. Alternatively, a reference to the composition of the buffer should be given. Further details are provided in the *Biochemical Journal* (1978) **169**, 9.

When describing solutions containing organic anions and their parent acids, the salt designator (e.g. lactate, urate, oxalate) should be used in preference to the name of the acid (lactic, uric, oxalic) unless it is certain that virtually all of the acid is in the undissociated form.

The composition of incubation media should be described, or a reference to the composition should be given.

3.5. Doses

Doses of drugs should be expressed in mass terms, e.g. milligrams (mg) or grams (g), and also (in parentheses) in molar terms, e.g. mmol, mol, where this appears to be relevant. Molecular weights of many drugs may be found in *The Merck Index*, 8th edn, Merck and Co. Inc., N.J., U.S.A.

3.6. Enzymes

Nomenclature should follow that given in *Enzyme Nomenclature* (1978), Academic Press,

London and New York, and Enzyme Commission (EC) number should be quoted at the first mention. Where an enzyme has a commonly used informal name, this may be employed after the first formal identification. A unit of enzyme activity should preferably be expressed as that amount of material which will catalyse transformation of 1 μ mol of the substrate/min under defined conditions, including temperature and pH. Alternatively, or when the natural substrate has not been fully defined, activity should be expressed in terms of units of activity relative to that of a recognized reference preparation, assayed under identical conditions. Activities of enzymes should normally be expressed as units/ml or units/mg of protein.

3.7. Evaluation of measurement procedures

When a new measuring procedure has been used, or when an established procedure has been applied in a novel fashion, an estimate of the precision of the procedure should be given. This should, as far as possible, indicate what sources of variation have been included in this estimate, e.g. variation of immediate replication, variation within different times of day, or from day to day etc.

If the precision of measurement varies in proportion to the magnitude of the values obtained, it can best be expressed as the coefficient of variation; otherwise it should be expressed by an estimate of the (constant) standard error of a single observation, or by estimates at several points within the range of observed values.

When recovery experiments are described the approximate ratio of the amount added to the amount already present and the stage of the procedure at which the addition was made should be stated.

3.8. Figures and Tables

These are expensive to print and their number should be kept to a minimum. Their appropriate position in the paper should be indicated in the margin of the text. References to Figures and Tables should be in Arabic numerals, e.g. Fig. 3, and they should be numbered in order of appearance. In general, the same data should not be presented in both a Figure and a Table.

Figures, with captions attached, should be supplied as original drawings or matt photographs together with photocopies. All Figures should have their number and the authors' names written in pencil on the back; the top of the Figure should be indicated with a pencilled arrow. A horizontal or square layout is preferred to a vertical one. Acceptable symbols for experimental points are ●,

▲, ■, ○, △, □. The symbols × or + must be avoided. The same symbols must not be used for two curves where the points might be confused. For scatter diagrams, solid symbols are preferred. When a particular variable appears in more than one Figure, the same symbol should be used for it throughout, if possible.

Curves should not be drawn beyond the experimental points, nor should axes extend appreciably beyond the data. Only essential information that cannot readily be included in the legend should be written within the Figure.

Figures for half-tone reproduction should be submitted as glossy prints. They are particularly expensive to print and their use should be avoided as far as possible.

Tables should be typed separately from the text. They should have an underlined title followed by any legend.

Captions for the Figures, and titles and legends for the Tables, should make them readily understandable without reference to the text. Adequate statistical information, including that on regression lines, should be included in Figure captions where appropriate.

3.9. Footnotes

These should be avoided as far as possible but where they are used in Tables they should be identified by the symbols * † ‡ § || ¶, in that order.

3.10. Isotope measurements

The information given should include (a) conditions of radioactivity counting, e.g. infinitely thick, infinitely thin; (b) the nature of the phosphor used in liquid-scintillation counting; (c) details of corrections made to the observed count rate, e.g. for 'quenching' or 'cross-over'; (d) standard deviation of the results or a statement of the minimum total counts above background collected and the background value.

In general the specific radioactivity of the starting materials should be given, preferably in terms of radioactivity per unit weight or, for stable isotopes, as atoms % excess.

Pending the general introduction of SI units radioactivity should continue to be expressed in terms of the curie (Ci) followed by the corresponding figure in terms of the becquerel (Bq: disintegrations/s), in parentheses, and suitably rounded.

3.11. Radionuclide applications in man

If new or modified radionuclide applications in man are described, an estimate of the maximal

possible radiation dose to the body and critical organs should be given.

For the time being this can continue to be expressed in rems, but with the corresponding figure in sieverts (Sv) given in parentheses after it.

3.12. Methods

In describing certain techniques, namely centrifugation (when the conditions are critical), chromatography and electrophoresis, authors should follow the recommendations published by the Biochemical Society (currently, *Biochemical Journal* (1978) 169, 1-21).

3.13. Nomenclature of disease

This should follow the *International Classification of Disease* (8th revision, World Health Organization, Geneva, 1969) as far as possible.

3.14. Powers in Tables and Figures

Care is needed where powers are used in Table headings and in Figures to avoid numbers with an inconvenient number of digits. For example: (i) an entry '2' under the heading 10^3k means that the value of k is 0.002; an entry '2' under the heading $10^{-3}k$ means that the value of k is 2000. (ii) A concentration 0.00015 mol/l may be expressed as 0.15 under the heading 'concn. (mmol/l)' or as 150 under the heading 'concn. (μ mol/l)' or as 15 under the heading ' $10^3 \times$ concn. (mol/l)', but not as 15 under the heading 'concn. (mol/l $\times 10^{-3}$)'.

3.15. References

These should be in alphabetical order of first authors. The full title of the paper, the journal and the first and last page numbers should be given, e.g.

CLARK, T.J.H., FREEDMAN, S., CAMPBELL, E.J.M. & WINN B.R. (1969) The ventilatory capacity of patients with chronic airways obstruction. *Clinical Science*, 36, 307-316.

When the quotation is from a book, the following format should be used, giving the relevant page or chapter number:

MOLLISON, P.L. (1967) *Blood Transfusion in Clinical Medicine*, 4th edn, p. 50. Blackwell Scientific Publications, Oxford.

REID, L. (1968) In: *The Lung*, p. 87. Ed. Liebow, A.A. & Smith, D.E. Williams and Wilkins, Baltimore.

References in the text should follow the style: Clark, Freedman, Campbell & Winn (1969) on the first quotation and, if there are more than two authors, 'Clark *et al.* (1969)' or '(Clark *et al.*, 1969)' in subsequent quotations.

References to 'personal communications' and 'unpublished work' should appear in the text only and not in the list of references. The name and

initials of the source of information should be given. When the reference is to material that has been accepted for publication but has not yet been published, this should be indicated in the list of references by 'In press' together with the name of the relevant journal and, if possible, the expected date of publication. If such a citation is of major relevance to the manuscript submitted for publication authors are advised that the editorial process might be expedited by the inclusion of a copy of such work. In the case of quotations from personal communications the authors should state in the covering letter that permission for quotation has been obtained.

3.16. Solutions

Concentration of solutions should be described where possible in molar terms (mol/l and subunits thereof), stating the molecular particle weight if necessary. Values should not be expressed in terms of normality or equivalents. Mass concentration should be expressed as g/l or subunits thereof, for example mg/l or $\mu\text{g/l}$. For solutions of salts, molar concentration is always preferred to avoid ambiguity as to whether anhydrous or hydrated compounds are used. Concentrations of aqueous solutions should be given as mol/l or mol/kg (g/l or g/kg if not expressed in molar terms) rather than % (w/v) or % (w/w). It should always be made clear whether concentrations of components in a reaction mixture are final concentrations or the concentrations in solutions added.

3.17. Spectrophotometric data

The term 'absorbance' [$\log(I_0/I)$] should be used rather than 'optical density' or 'extinction'. The solvent, if other than water, should be specified. Symbols used are: A , absorbance; a , specific absorption coefficient ($\text{litre g}^{-1} \text{cm}^{-1}$) (alternatively use $A_{1\text{cm}}^{1\%}$); ϵ , molar absorption coefficient (the absorbance of a molar solution in a 1 cm light-path) ($\text{litre mol}^{-1} \text{cm}^{-1}$, not $\text{cm}^2 \text{mol}^{-1}$).

3.18. Spelling

Clinical Science uses as standards for spelling the *Concise* or *Shorter Oxford Dictionary of Current English* (Clarendon Press, Oxford) and *Butterworth's Medical Dictionary* (Butterworths, London).

3.19. Statistics

Papers are frequently returned for revision (and their publication consequently delayed) because the authors use inappropriate statistical methods. Two

common errors are the use of means, standard deviations and standard errors in the description and interpretation of grossly non-normally distributed data and the application of t -tests for the significance of difference between means in similar circumstances, or when the variances of the two groups are non-homogeneous. In some circumstances it may be more appropriate to provide a 'scattergram' than a statistical summary.

A reference should be given for all methods used to assess the probability of a result being due to chance. The format for expressing mean values and standard deviations or standard errors of the mean is, for example: mean cardiac output 10.4 l/min (SD 1.2; $n = 11$). Degrees of freedom should be indicated where appropriate. Levels of significance are expressed in the form $P < 0.01$.

3.20. Trade names

The name and address of the supplier of special apparatus and of biochemicals should be given. In the case of drugs, approved names should always be given with trade names and manufacturers in parentheses.

3.21. Computer modelling

Papers concerned primarily with computer modelling techniques are acceptable provided that use of such techniques leads to a clear choice between two or more alternative hypotheses, or to the formulation of a new hypothesis amenable to experimental challenge or verification, or provides some new insight into the behaviour of a particular physiological system. Extensive technical details of hardware and software should not be given.

4. UNITS: THE SI SYSTEM

The recommended *Système International* (SI) units [see *Quantities, Units and Symbols*, 2nd edn (1975) The Royal Society, London] are used by *Clinical Science*. All papers submitted should use these units except for blood pressure values, which should be expressed in mmHg, or gas tensions, where values at the author's discretion may be given as mmHg (with kPa in parentheses) or as kPa (with mmHg in parentheses) in the text and either as mmHg or as kPa in Figures, which (if practicable) should have scales in both units. Airways pressure should be expressed in kPa. Where molecular weight is known, the amount of a chemical or drug should be expressed in mol or in an appropriate subunit, e.g. mmol. Energy should be expressed in joules (J).

The basic SI units and their symbols are as follows:

Physical quantity	Name	Symbol
length	metre	m
mass	kilogram	kg
time	second	s
electric current	ampere	A
thermodynamic temperature	kelvin	K
luminous intensity	candela	cd
amounts of substance	mole	mol

The following are examples of derived SI units:

Physical quantity	Name	Symbol	Definition
energy	joule	J	$\text{kg m}^2 \text{s}^{-2}$
force	newton	N	$\text{kg m s}^{-2} = \text{J m}^{-1}$
power	watt	W	$\text{kg m}^2 \text{s}^{-3} = \text{J s}^{-1}$
pressure	pascal	Pa	$\text{kg m}^{-1} \text{s}^{-2} = \text{N m}^{-2}$
electric charge	coulomb	C	A s
electric potential difference	volt	V	$\text{kg m}^2 \text{s}^{-2} \text{A}^{-1} = \text{J A}^{-1} \text{s}^{-1}$
electric resistance	ohm	Ω	$\text{kg m}^2 \text{s}^{-3} \text{A}^{-2} = \text{V A}^{-1}$
electric conductance	siemens	S	$\text{kg}^{-1} \text{m}^{-2} \text{s}^3 \text{A}^2 = \Omega^{-1}$
electric capacitance	farad	F	$\text{A}^2 \text{s}^3 \text{kg}^{-1} \text{m}^{-2} = \text{A s V}^{-1}$
frequency	hertz	Hz	s^{-1}
volume	litre	l	10^{-3} m^3

The word 'litre' has been accepted as a special name for cubic decimetre (1 litre = 1 dm³).

Both the basic and derived SI units, including the symbols of derived units that have special names, may be preceded by prefixes to indicate multiples and submultiples. The prefixes should be as follows:

Multiple	Prefix	Symbol	Multiple	Prefix	Symbol
10 ⁶	mega	M	10 ⁻³	milli	m
10 ³	kilo	k	10 ⁻⁶	micro	μ
10 ²	hecto	h*	10 ⁻⁹	nano	n
10	deka	da	10 ⁻¹²	pico	p
10 ⁻¹	deci	d*	10 ⁻¹⁵	femto	f
10 ⁻²	centi	c*			

* To be avoided where possible (except for cm).

Compound prefixes should not be used, e.g. 10⁻⁹ m should be represented by 1 nm, not 1 μm .

Notes:

(i) Full stops are not used after symbols.

(ii) Minutes (min), hours (h), days and years will continue to be used in addition to the SI unit of time [the second (s)].

(iii) The solidus may be used in a unit as long as it does not have to be employed more than once, e.g. mmol/l is acceptable, but ml/min/kg is not, and should be replaced by $\text{ml min}^{-1} \text{kg}^{-1}$.

5. ABBREVIATIONS, CONVENTIONS, DEFINITIONS, SYMBOLS AND SPECIAL COMMENTS

As well as standard symbols and abbreviations that have been accepted by international bodies, and which can be used without definition, this list shows selected abbreviations in the form of groups of capital letters (e.g. ALA, ECF, MCHC) which when used must be defined in the text as indicated on p. iv. The standard abbreviations for amino acids are only for use in Figures and Tables or for peptide sequences.

absorbance	A
acceleration due to gravity	g
adenosine 3':5'-cyclic monophosphate	cyclic AMP
adenosine 5'-phosphate	AMP
adenosine 5'-pyrophosphate	ADP
adenosine 5'-triphosphate	ATP
adenosine triphosphatase	ATPase
adrenocorticotrophic hormone	ACTH
adrenoreceptor (see also blocking agents)	
alanine	Ala
alternating current	a.c.
alveolar minute ventilation	\dot{V}_A
alveolar to arterial oxygen tension difference	$(P_{A,O_2} - P_{a,O_2})$
ampere	A
aminolaevulinic acid	ALA
angiotensin	ANG; reference amino acid abbreviations are used as prefix within brackets: e.g. [Sar ¹ ,Val ² ,Ala ⁸]ANG
Ångstrom (Å)	not used; express in nm (1 Ångstrom = 10 ⁻¹ nm)
antidiuretic hormone	ADH (when referring to the physiological secretion)
arginine	Arg
arteriovenous	a-v: permitted in Figures and Tables
asparagine	Asn
aspartic acid	Asp
atmosphere (unit of pressure)	not used; express in kPa (1 atmosphere = 101.325 kPa)
atomic weight	at. wt.
becquerel	Bq (1 d.p.s.)
blocking agents	e.g. β -adrenoreceptor antagonists preferred
blood pressure	express in mmHg
blood urea nitrogen	not used; recalculate as urea, express in mmol/l
blood volume	BV
body temperature and pressure, saturated	BTPS

British Pharmacopoeia	write in full and give edition	electromotive force	e.m.f.
calculated	calc. (in Tables only)	electron spin resonance	e.s.r.
'Calorie' (= 1000 cal)	<i>not used</i> ; recalculate as kilojoules (1 'Calorie' = 4.184 kJ)	electronvolt	eV (for radiation energies)
carbon dioxide output (in respiratory physiology)	\dot{V}_{CO_2} ; express in ml STP/min	equation	eqn.
cardiac frequency	f_c ; in beats/min	equivalents (amount of a chemical)	<i>not used</i> ; recalculate in molar terms
cardiac output	express in l/min	erythrocyte count	express as 10^{12} cells/l
centimetre	cm	erythrocyte sedimentation rate	ESR
clearance of x	C_x	ethanol, ethanolic	not ethyl alcohol or alcoholic
coenzyme A and its acyl derivatives	CoA and acyl-CoA	ethylenediaminetetra-acetate exchangeable	EDTA Na_a , K_c etc., for total exchangeable sodium, potassium etc.
compare	cf.	Experiment (with reference numeral)	Expt.; plural, Expts.
complement fractions	C1–C9	expired minute ventilation	\dot{V}_E
compliance (respiratory physiology)	C; express in 1 kPa^{-1}	extinction	use absorbance
concentrated	conc.	extracellular fluid	ECF
concentration	concn.; may be denoted []; e.g. plasma $[\text{HCO}_3^-]$	extracellular fluid volume	ECFV
conductance (respiratory physiology)	G; express in $1 \text{ s}^{-1} \text{ kPa}^{-1}$	extraction ratio of x (renal)	E_x
correlation coefficient	r; may be used without definition	Figure (with reference numeral)	Fig.; plural, Figs.
counts/min, counts/s	c.p.m., c.p.s.	filtered load of x (renal)	F_x
cubic centimetres	use ml	follicle-stimulating hormone	FSH
curie	Ci ($1 \text{ Ci} = 3.7 \times 10^{10}$ d.p.s.)	forced expiratory volume in 1.0 s	FEV _{1.0}
cycle/s	Hz	fractional concentration in dry gas	F
cysteine	Cys	fractional disappearance rate	k (as in $A = A_0 e^{-kt}$)
dates	e.g. 11 August 1970	frequency of respiration	f_R ; in breaths/min
dead-space minute ventilation	\dot{V}_D	functional residual capacity	FRC
dead-space volume	V_D	gas-liquid chromatography	g.l.c.
degrees, Celsius or centigrade	$^\circ\text{C}$	gas transfer factor	T; in $\text{mmol min}^{-1} \text{ kPa}^{-1}$
deoxy (prefix)	<i>not deoxy</i>	glomerular filtration rate	GFR
deoxycorticosterone	DOC	glutamic acid	Glu
deoxycorticosterone acetate	DOCA	glutamine	Gln
deoxyribonucleic acid	DNA	glutathione	GSH (reduced); GSSG (oxidized)
dialysate	diffusate preferred; 'dialysate' should be clearly defined	glycine	Gly
diethylaminoethylcellulose	DEAE-cellulose	gram(me)	g
differential of x with respect to time	\dot{x} (= dx/dt)	gravitational field, unit of (9.81 m s^{-2})	g
1,25-dihydroxycholecalciferol	1,25-(OH) ₂ D ₃	growth hormone	GH; if human, HGH
dilute	dil.	haematocrit	<i>not allowed</i> ; use packed cell volume (PCV)
2,3-diphosphoglycerate	2,3-DPG	haemoglobin	Hb; express in g/dl
direct current	d.c.	half-life	$t_{1/2}$
disintegrations/min	d.p.m.	hertz (s^{-1})	Hz
disintegrations/s	d.p.s.	histidine	His
dissociation constant		hour	h
acidic	K_a	human chorionic gonadotropin	HCG
basic	K_b	human placental lactogen	HPL
apparent	e.g. K'_a	hydrocortisone	use cortisol
minus log of	pK	hydrogen ion activity minus log of	aH; express in nmol/l pH
doses	avoid Latin designations such as b.d. and t.i.d.	25-hydroxycholecalciferol	25-(OH)D ₃
dyne	<i>not used</i> ; express in newtons ($1 \text{ dyne} = 10^{-5} \text{ N}$)	hydroxyproline	Hyp
elastance	E; express in Pa m^{-3}	immunoglobulins	IgA, IgD, IgE, IgG, IgM
electrocardiogram	ECG		
electroencephalogram	EEG		

injection routes:	use abbreviations only in Figures	millimetre of mercury	mmHg; for blood pressure and, at authors' discretion, for gas tensions: see p. vi (1 mmHg = 0.133 kPa)
intra-arterial	i.a.		
intramuscular	i.m.		
intraperitoneal	i.p.		
intravenous	i.v.	millimolar (concentration)	mmol/l; <i>not</i> mM
subcutaneous	s.c.	millimole	mmol
international unit	i.u. (definition and reference should be given for uncommon or ambiguous applications, e.g. enzymes)	minimum	min.
		minute (60 s)	min
		molal	mol/kg
		molar (concentration)	mol/l; <i>not</i> M
		molar absorption coefficient	ϵ (the absorbance of a molar solution in a 1 cm light-path)
intracellular fluid	ICF		mol
intracellular fluid volume	ICFV	mole	mol. wt.
ionic strength	<i>I</i>	molecular weight	NAD if oxidation state not indicated
isoleucine	Ile	nicotinamide-adenine dinucleotide	NAD ⁺ if oxidized
isotonic	<i>not used</i> ; specify composition of fluid, e.g. NaCl, 150 mmol/l		NADH if reduced
			NADP if oxidation state not indicated
isotopically labelled compounds	e.g. [U- ¹⁴ C]glucose, [1- ¹⁴ C]glucose, sodium [1- ¹⁴ C]-acetate; <i>use</i> ¹³¹ I-labelled albumin, <i>not</i> [¹³¹ I]albumin	nicotinamide-adenine dinucleotide phosphate	NADP ⁺ if oxidized
			NADPH if reduced
			should not be used to denote the concentration or osmolarity of a solution
		normal	<i>use</i> standard temperature and pressure (STP)
joule	J	normal temperature and pressure	
kilogram(me)	kg		
kilopond	<i>not used</i> ; 1 kilopond = 9.8067 N	nuclear magnetic resonance number (in enumerations)	n.m.r.
		observed	no. (in Tables only)
lactate dehydrogenase	LDH	ohm	obs. (in Tables only)
leucine	Leu	ornithine	Ω
leucocyte count	express as 10 ⁹ cells/l	ortho-	Orn
lipoproteins (serum)		orthophosphate (inorganic)	<i>o-</i>
high density	HDL	osmolality	<i>P</i> ₁
low density	LDL		express in mol (or mmol)/kg
very low density	VLDL	oxygen uptake per minute (in respiratory physiology)	$\dot{V}O_2$; express in ml STP/min
litre	l (write in full if confusion with the numeral 1 is possible)	packed cell volume	PCV
		page, pages	p., pp.
logarithm (base 10)	log	para-	<i>p-</i>
logarithm (base e)	ln	para-aminohippurate	PAH
luteinizing hormone	LH	partial pressure	<i>P</i> ; express in either kPa or mmHg (see p. vi)
lysine	Lys		
maximum	max.	e.g. alveolar, of O ₂	<i>P</i> _{A,O₂}
mean corpuscular haemoglobin	MCH; express in pg	arterial, of CO ₂	<i>P</i> _{a,CO₂}
mean corpuscular haemoglobin concentration	MCHC; express in g/dl	capillary, of O ₂	<i>P</i> _{C,O₂}
mean corpuscular volume	MCV; express in fl (1 $\mu\text{m}^3 = 1 \text{ fl}$)	mixed venous, of CO ₂	<i>P</i> \bar{v} ,CO ₂
		pascal	Pa
median lethal dose	LD ₅₀	per	/
meta-	<i>m-</i>	per cent	%
melting point	m.p.	petroleum ether	<i>not used</i> ; <i>use</i> light petroleum and give boiling range
methanol, methanolic	<i>not</i> methyl alcohol		
methionine	Met	phenylalanine	Phe
metre	m	plasma renin activity	express as pmol of angiotensin I h ⁻¹ ml ⁻¹
Michaelis constant	<i>K</i> _m		
micromole	μmol	plasma volume	PV
micron (10 ⁻⁶ m)	μm ; <i>not</i> μ	poise	1 poise = 10 ⁻¹ N s m ⁻²
milliequivalent	<i>not used</i> ; give amount in mmol		
millilitre	ml		

potential difference	p.d.	specific conductance of	sGaw; express in
power output	W (1 W = 0.1635 kpm/min)	airways	$s^{-1} \text{ kPa}^{-1}$
precipitate	ppt.	standard deviation	SD } may be used SEM } without definition
pressure	P; express in kPa (except for blood pressures and gas tensions: see p. 6); 1 kPa = 7.5 mm Hg	standard error of the mean	
probability of an event being due to chance alone	P	standard temperature and pressure	STP
proline	Pro	steroid nomenclature	see <i>Biochemical Journal</i> (1969) 113, 5–28; (1972) 127, 613–617
protein-bound iodine (plasma)	PBI	sulphydryl	use thiol or SH
pulmonary capillary blood flow	\dot{Q}_c	sum	Σ
pyrophosphate (inorganic)	PPi	Svedberg unit	S
rad (radiation dose; 10^{-5} J absorbed/g of material)	not abbreviated	temperature (absolute)	T
red blood cell	use erythrocyte; express counts as 10^{12} cells/l	(empirical)	t
red cell mass	RCM	temperature, thermodynamic	$^{\circ}\text{K}$
relative band speed (partition chromatography)	R_F	thin-layer chromatography	t.l.c.
rem	100 ergs/g \times quality factor	threonine	Thr
renin	see plasma renin activity	thyrotrophic hormone	TSH
residual volume	RV	thyrotrophin-releasing hor- mone	TRH
resistance (rheological)	R; express in $\text{kPa l}^{-1} \text{ s}$	tidal volume	V_T
respiratory exchange ratio (pulmonary)	R	time (symbol)	t
respiratory quotient (metabolic)	RQ	time of day	e.g. 18.15 hours
revolutions	rev.	torr	not used; use kPa (1 torr = 0.133 kPa)
rev./min	not r.p.m.; use g if possible (see p. viii)	total lung capacity	TLC
ribonucleic acid	RNA	tryptophan	Trp
röntgen	R	tubular maximal reabsorptive capacity for x	$T_{m,x}$
saturation	S, e.g. S_a, O_2 for arterial oxygen saturation (see partial pressure for other analogous abbreviations)	tyrosine	Tyr
second (time)	s	ultraviolet	u.v.
serine	Ser	urinary concentration of x	U_x
sievert	Sv (1 J/kg \times quality factor)	valency	e.g. Fe^{2+} , not Fe^{++}
solvent systems	e.g. butanol/acetic acid/ water (4:1:1, by vol.), butanol/ acetic acid (4:1, v/v)	valine	Val
species	sp., plural spp.	variance ratio	F
specific activity	sp. act. Confusion must be avoided between e.g. specific radioactivity and the specific activity of an enzyme	vascular resistance	express in $\text{kPa l}^{-1} \text{ s}$ (with value in dyne cm s^{-5} in parentheses); primary values of dif- ferential vascular pres- sure (mmHg) and flow (l/min) should always also be given in Tables or text as appropriate
		velocity	v; express as m s^{-1}
		venous admixture	\dot{Q}_{va}
		veronal	used only for buffer mix- tures; otherwise use 5,5'-diethylbarbituric acid
		viscosity, dynamic	η
		viscosity, kinematic	ν
		vital capacity	VC
		volt	V
		volume of blood (in cardio- respiratory physiology)	\dot{Q} ; use \dot{Q} for blood flow rate
		watt	W
		wavelength	λ
		weight	wt.
		white blood cell	use leucocyte; express counts as 10^9 cells/l

CONTENTS

VOL. 58, No. 1

JANUARY 1980

Guidance for Authors	i-x
Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat. E. S. MARKS, R. F. BING, H. THURSTON and J. D. SWALES	1-6
Modulation of the baroreceptor reflex by angiotensin II and other vasoactive drugs in anaesthetized greyhounds. J. D. MARKER, T. S. MILES and G. C. SCROOP	7-13
Response of chronic renovascular hypertension to surgical correction or prolonged blockade of the renin-angiotensin system by two inhibitors in the rat. H. THURSTON, R. F. BING, E. S. MARKS and J. D. SWALES	15-20
Baroreflex sensitivity in renal failure. O. TOMIYAMA, T. SHIIGAI, T. IDEURA, K. TOMITA, Y. MITO, S. SHINOHARA and J. TAKEUCHI	21-27
Disappearance of angiotensin II and noradrenaline from the renal and femoral circulations of the dog. M. J. S. MILLER and G. C. SCROOP	29-35
Sequential changes in plasma noradrenaline during bicycle exercise. R. D. S. WATSON, C. A. HAMILTON, D. H. JONES, J. L. REID, T. J. STALLARD and W. A. LITTLER	37-43
Metabolism of vasoactive hormones in human isolated lung. F. AL-UBAIDI and Y. S. BAKHLE	45-51
Ultrasound measurements of pulse-wave velocity in the peripheral arteries of diabetic subjects. J. H. B. SCARPELLO, T. R. P. MARTIN and J. D. WARD	53-57
Peripheral resistance to the cellular action of insulin in obese diabetic subjects <i>in vivo</i> . J. P. D. RECKLESS and D. J. GALTON	59-63
Sieving studies in 'urea-induced nephropathy' in the dog. Y. VANRENTERGHEM, R. VANHOLDER, M. LAMMENS-VERSLUPE and P. P. LAMBERT	65-75
The effect of mineralocorticoid administration on urine free dopamine in man. N. S. OATES, C. M. PERKINS and M. R. LEE	77-82
An evaluation of the clinical potential of a comprehensive model of human respiration in artificially ventilated patients. C. J. HINDS, D. INGRAM, L. ADAMS, P. V. COLE, C. J. DICKINSON, J. KAY, J. R. KRAPEZ and J. WILLIAMS	83-91
Equilibration of tracer radioiron with body iron. R. W. CHARLTON, L. P. FATTI, S. R. LYNCH, J. D. TORRANCE and T. H. BOTHWELL	93-100
SHORT COMMUNICATIONS	
Long-term clearance of [⁵⁷ Co]cyanocobalamin in vegans and pernicious anaemia. S. AMIN, T. SPINKS, A. RANICAR, M. D. SHORT and A. V. HOFFBRAND	101-103
Serum testosterone depression associated with hypoxia in respiratory failure. P. D'A. SEMPLE, G. H. BEASTALL, W. S. WATSON and R. HUME	105-106
Transport of lignocaine by rabbit choroid plexus <i>in vitro</i> . R. SPECTOR	107-109
The relationship between plasma biotin concentration and circulating leucocyte β -methylcrotonyl-CoA carboxylase and propionyl-CoA carboxylase. K. BARTLETT, T. HORSBURGH and D. GOMPERTZ	111-114
The influence of physical activity on arterial pressure during ambulatory recording in man. D. B. ROWLANDS, T. J. STALLARD, R. D. S. WATSON and W. A. LITTLER	115-117

Editorial Review: Pulmonary gas exchange. J. M. B. HUGHES	119-125
<hr/>	
Acid-base changes after cardiorespiratory arrest in the dog. P. V. GREENWOOD, R. E. ROSSALL and C. T. KAPPAGODA	127-133
Growth hormone secretion in hypertensive patients: evidence for a derangement in central adrenergic function. C. BARBIERI, C. FERRARI, R. CALDARA and G. CURTARELLI	135-138
Fate of vasopressin perfused into nephrons of Wistar and Brattleboro (diabetes insipidus) rats. M. D. LINDHEIMER, A. REINHARZ, A. GRANDCHAMP and M. B. VALLOTTON	139-144
Serum inorganic fluoride: changes related to previous fluoride intake, renal function and bone resorption. CHRISTINE WATERHOUSE, D. TAVES and A. MUNZER	145-152
Correlation of plasma phenformin concentration with metabolic effects in normal subjects. M. NATTRAS, KAREN SIZER and K. G. M. M. ALBERTI	153-155
Creatine kinase-1 is principally inactivated in serum by complexing with immunoglobulin-G. D. A. NEALON and A. R. HENDERSON	157-160
An association between plasma progesterone and erythrocyte carbonic anhydrase I concentration in women. J. PACIOREK and N. SPENCER	161-164
 SHORT COMMUNICATIONS	
Characterization of the storage material of peripheral lymphocytes in aspartylglycosaminuria. P. MAURY and J. PALO	165-168
Application of the occupancy principle in studies of the metabolism of vitamin B ₁₂ in man. R. G. BESSENT, W. S. WATSON, CAROLINE M. L. A. MACDONALD and J. F. ADAMS	169-171
Erythrocyte superoxide dismutase activity in Fanconi's anaemia. S. OKAHATA, Y. KOBAYASHI and T. USUI	173-175
 CORRESPONDENCE SECTION	
Further studies on bone blood flow and age in the rat. P. TOTHILL and J. N. MACPHERSON	177-178
Salivary ethanol. B. M. WRIGHT	178-179
Correlation of ethanol concentrations in blood and saliva. J. P. ROYSTON	179-181
MEDICAL RESEARCH SOCIETY (Meeting on 7 and 8 December 1979) Communications	1P-32P

Editorial Review: Nutritional effects on thyroid and catecholamine metabolism. R. T. JUNG, P. S. SHETTY and W. P. T. JAMES	183-191
<hr/>	
Cardiovascular responses to graded reductions of central blood volume in normal subjects and in patients with diabetes mellitus. T. BENNETT, D. J. HOSKING and J. R. HAMPTON	193-200

Prostaglandins as mediators of bone resorption in renal and breast tumours. M. GREAVES, K. J. IBBOTSON, D. ATKINS and T. J. MARTIN	201-210
Activities of some free-radical scavenging enzymes and glutathione concentrations in human and rat liver and their relationship to the pathogenesis of tissue damage in iron overload. CLARE SELDEN, CAROL A. SEYMOUR and T. J. PETERS	211-219
Influx of glycylsarcosine and L-lysyl-L-lysine into hamster jejunum <i>in vitro</i> . E. TAYLOR, D. BURSTON and D. M. MATTHEWS	221-225
Effect of spironolactone and aldosterone regulation in man. R. C. GAILLARD, A. M. RIONDEL, P. CHABERT and M. B. VALLOTTON	227-233
Assessment of plasma 25-hydroxyvitamin D response to ultraviolet irradiation over a controlled area in young and elderly subjects. M. DAVIE and D. E. M. LAWSON	235-242
Indium (¹¹¹ In)-labelled human platelets: optimal method. R. J. HAWKER, LINDA M. HAWKER and A. R. WILKINSON	243-248
Practical importance of a preceding full inhalation or exhalation upon the measurement of airway resistance. T. HIGENBOTTAM and T. J. H. CLARK	249-253
SHORT COMMUNICATIONS	
Effect of a natural and artificial menopause on serum, urinary and erythrocyte magnesium. R. LINDSAY, D. M. HART and C. FORREST	255-257
Sialic acid and the microheterogeneity of human serum ferritin. S. J. CRAGG, M. WAGSTAFF and M. WORWOOD	259-262
VOL. 58, No. 4	APRIL 1980
Estimation of cardiac output from the rate of change of alveolar carbon dioxide pressure during rebreathing. MARY WINSBOROUGH, J. N. MILLER, D. W. BURGESS and G. LASZLO	263-270
Cardiogenic hypertension: experimental evidence from a comparison between intravenous and intracoronary administration of dobutamine in conscious dogs. J.-F. LIARD	271-277
Selective and non-selective β -adrenoreceptor blockade in the human forearm. O. J. HARTLING, I. NOER, T. L. SVENDSEN, J. P. CLAUSEN and J. TRAP-JENSEN	279-286
The relative merits of various techniques for measuring radiocalcium absorption. R. WOOTTON and J. REEVE	287-293
Monocytes in inflammatory bowel disease: monocyte and serum lysosomal enzyme activity. A. S. MEE and D. P. JEWELL	295-300
Relationship between the basal blood alanine concentration and the removal of an alanine load in various clinical states in man. M. ELIA, VERA ILIC, SUSAN BACON, D. H. WILLIAMSON and R. SMITH	301-309
Urinary conjugates of 4-hydroxy-3-methoxyphenylethylene glycol do not provide an index of brain amine turnover in man. A. R. BOOBIS, S. MURRAY, D. H. JONES, J. L. REID and D. S. DAVIES	311-316
Lack of effect of somatostatin on iodothyronine release from the perfused canine thyroid. P. LAURBERG	317-320
Rat liver storage iron and plasma ferritin during D-galactosamine-HCl-induced hepatitis. F. M. J. ZUYDERHOUDT, G. G. A. JÖRNING, J. G. DE HAAN, G. SAMSON and J. VAN GOOL	321-325

Creatinine metabolism in chronic renal failure. W. E. MITCH, V. U. COLLIER and M. WALSER	327-335
--	---------

SHORT COMMUNICATIONS

Effects of indomethacin on the metabolism of glycerol by rat-kidney tubules: an alternative explanation for the enhancement of glycerol-induced acute renal failure by indomethacin. ELIZABETH CRAIG, G. J. COONEY and A. G. DAWSON	337-340
Rise in plasma alkaline phosphatase at the menopause. R. G. CRILLY, M. M. JONES, A. HORSMAN and B. E. C. NORDIN	341-342

VOL. 58, No. 5

MAY 1980

Editorial Review: Control of the pattern of breathing. H. GAUTIER	343-348
---	---------

Haemodynamics in patients with pheochromocytoma. J. A. LEVENSON, M. E. SAFAR, G. M. LONDON and A. CH. SIMON	349-356
The effects of isoprenaline, atropine and dobutamine on ventricular volume curves obtained by radionuclide ventriculography. A. L. MUIR, W. J. HANNAN, R. P. SAPRU, A. K. BOARDMAN, P. K. WRAITH and H. M. BRASH	357-364
Parathyroid hormone- and deoxycorticosterone acetate-induced hypertension in the rat. A. BERTHELOT and A. GAIRARD	365-371
The use of isolated digital arteries to study factors influencing adrenergic-transmitter release in man. R. E. RITTINGHAUSEN and R. F. W. MOULDS	373-378
Renal metabolism of paracetamol: studies in the isolated perfused rat kidney. SANDRA HART, I. CALDER, B. ROSS and J. TANGE	379-384
Basal activity of the natriuretic factor extracted from the rat kidney as a function of the diet and its role in the regulation of the acute sodium balance. F. LOUIS and H. FAVRE	385-391
The role of prostaglandins in glucagon-induced natriuresis. M. A. KIRSCHENBAUM and E. T. ZAWADA	393-401
The induction of lysosomal enzyme release from leucocytes of normal and emphysematous subjects and the effects of tobacco smoke upon phagocytosis. D. C. S. HUTCHISON, R. DESAI, D. BELLAMY and H. BAUM	403-409

SHORT COMMUNICATIONS

Heart-rate changes on standing in elderly patients with orthostatic hypotension. N. J. WHITE	411-413
Insulin-induced renin release: blockade by indomethacin in the rat. W. B. CAMPBELL and JUDITH A. ZIMMER	415-418
Enzyme induction and serum and lipoprotein lipids: a study of glutethimide in normal subjects. C. H. BOLTON, LYN JACKSON, C. J. C. ROBERTS and M. HARTOG	419-421
Erythrocyte catechol-O-methyltransferase activity and indices of sympathetic activity in man. G. A. FITZGERALD, C. A. HAMILTON, D. H. JONES and J. L. REID	423-425
Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. D. E. L. WILCKEN, VATSALA J. GUPTA and S. G. REDDY	427-430

Impaired intestinal absorption of dipeptide in tropical sprue patients in India. M. D. HELLIER, V. GANAPATHY, A. GAMMON, V. I. MATHAN and A. N. RADHAKRISHNAN	431-433
Plasma α_2 HS-glycoprotein concentration in Paget's disease of bone: its possible significance. B. A. ASHTON and R. SMITH	435-438
VOL. 58, No. 6	JUNE 1980
<hr/>	
Editorial Review: Hepatic plasma-membrane modifications in disease. W. H. EVANS	439-444
<hr/>	
The effect of captopril on blood pressure and angiotensins I, II and III in sodium-depleted dogs: problems associated with the measurement of angiotensin II after inhibition of converting enzyme. J. J. MORTON, M. TREE and J. CASALS-STENZEL	445-450
Preliminary evidence for the conversion of dog renin into a higher-molecular-weight form by cold storage. M. KAWAMURA, F. IKEMOTO and K. YAMAMOTO	451-456
Human lung adrenoreceptors studied by radioligand binding. P. J. BARNES, J. S. KARLINER and C. T. DOLLERY	457-461
Cyclic nucleotide excretion in human malignancies. N. H. HUNT, B. SMITH and R. PEMBREY	463-467
Urine concentration of 3-ethyl-5-hydroxy-4,5-dimethyl- Δ^3 -pyrrolin-2-one ('mauve factor') is not causally related to schizophrenia or to acute intermittent porphyria. A. GORCHEIN	469-476
Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase. G. H. ELDER, DIANE M. SHEPPARD, R. E. DE SALAMANCA and A. OLMOS	477-484
Determination of the pool size and synthesis rate of bile acids by measurements in blood of patients with liver disease. L. R. ENGELKING, S. BARNES, B. I. HIRSCHOWITZ, C. A. DASHER, J. G. SPENNEY and D. NAFTEL	485-492
Role of antidiuretic hormone in impaired urinary dilution associated with chronic bile-duct ligation. O. S. BETTER, G. A. AISENBREY, T. BERL, R. J. ANDERSON, W. A. HANDELMAN, S. L. LINAS, S. J. GUGGENHEIM and R. W. SCHRIER	493-500
Cooling responses in shivering and non-shivering dogs during induced hypothermia. C. D. AULD, I. M. LIGHT and J. N. NORMAN	501-506
Metabolic effects of the use of protein-sparing infusions in postoperative patients. K. J. FOSTER, K. G. M. M. ALBERTI, C. BINDER, LESLIE HINKS, S. KARRAN, PATRICIA SMYTHE, S. TALBOT, D. TURNELL and H. ØRSKOV	507-515
[15 N]Glycine metabolism in normal man: the metabolic α -amino-nitrogen pool. A. A. JACKSON and M. H. GOLDEN	517-522
The metabolism of a physiological dose of radioactive cholecalciferol (vitamin D ₃) to its hydroxylated metabolites in man. S. W. STANBURY and E. BARBARA MAWER	523-535
Histamine receptors in normal human bronchi. NOEMI M. EISER, JANE MILLS, K. D. MCRAE, P. D. SNASHALL and A. GUZ	537-544
SHORT COMMUNICATIONS	
Effect of phalloidin on biliary lipid secretion in rats MARTA DUBIN and S. ERLINGER	545-548

- The effects of the antagonists of the renin–angiotensin system on cardiovascular response to lower-body subatmospheric pressure in the anaesthetized cat. S. A. ADIGUN, D. P. CLOUGH, J. CONWAY and R. HATTON 549–552
- Effect of aging on energy-rich phosphagens in human skeletal muscles. P. MÖLLER, J. BERGSTRÖM, P. FÜRST and K. HELLSTRÖM 553–555